Results 11 to 20 of about 6,788,532 (255)

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

New England Journal of Medicine, 2017
X. Montalban, S. Hauser, L. Kappos, D. Arnold, A. Bar-Or, G. Comi, J. de Seze, G. Giovannoni, H. Hartung, B. Hemmer, F. Lublin, K. Rammohan, K. Selmaj, A. Traboulsee, A. Sauter, D. Masterman, P. Fontoura, S. Belachew, Hideki Garren, N. Mairon, P. Chin, J. Wolinsky   +21 more
semanticscholar   +3 more sources

Multiple Sclerosis

New England Journal of Medicine, 2018
D. Reich, C. Lucchinetti, P. Calabresi
semanticscholar   +4 more sources

Ocrelizumab versus Interferon Beta‐1a in Relapsing Multiple Sclerosis

New England Journal of Medicine, 2017
S. Hauser, A. Bar-Or, G. Comi, G. Giovannoni, Hans-Peter Hartung, B. Hemmer, F. Lublin, X. Montalban, K. Rammohan, K. Selmaj, A. Traboulsee, J. Wolinsky, D. Arnold, G. Klingelschmitt, D. Masterman, P. Fontoura, S. Belachew, P. Chin, N. Mairon, Hideki Garren, L. Kappos   +20 more
semanticscholar   +3 more sources

COVID-19 Vaccine Response in People with Multiple Sclerosis Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab, or Interferon Beta Therapy

Neurology and Therapy, 2023
Background Some multiple sclerosis (MS) disease-modifying therapies (DMTs) impair responses to vaccines, emphasizing the importance of understanding COVID-19 vaccine immune responses in people with MS (PwMS) receiving different DMTs.
Aliya Jaber, Meera Patel, Andrew Sylvester, Mary Yarussi, J. Tamar Kalina, Jason P. Mendoza, Robin L. Avila, Matthew A. Tremblay   +7 more
doaj   +1 more source

2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis.

Lancet Neurology, 2021
The 2015 Magnetic Resonance Imaging in Multiple Sclerosis and 2016 Consortium of Multiple Sclerosis Centres guidelines on the use of MRI in diagnosis and monitoring of multiple sclerosis made an important step towards appropriate use of MRI in routine ...
M. Wattjes, O. Ciccarelli, D. Reich, B. Banwell, N. Stefano, C. Enzinger, F. Fazekas, M. Filippi, J. Frederiksen, C. Gasperini, Y. Hacohen, L. Kappos, David K.B. Li, K. Mankad, X. Montalban, S. Newsome, Jiwon Oh, Jacqueline A Palace, M. Rocca, J. Sastre-Garriga, M. Tintoré, A. Traboulsee, H. Vrenken, T. Yousry, F. Barkhof, À. Rovira, M. Rocca, M. Tintoré, À. Rovira   +28 more
semanticscholar   +1 more source

A grounded theory analysis of the occupational impact of caring for a partner who has multiple sclerosis [PDF]

, 2006
Chronic progressive conditions such as multiple sclerosis impact engagement in and orchestration of daily occupations by people with the condition, and their family members.
Gough, B, Heward, K, Molineaux, M
core   +1 more source

“I need personal experiences or some sort of documentation”: a qualitative study on where people with multiple sclerosis seek information on dietary and herbal supplements

BMC Complementary Medicine and Therapies, 2021
Background The use of dietary and herbal supplements (DIHES) is widespread among people with multiple sclerosis (PwMS). PwMS are a highly informed patient group, and they use several types of sources to seek information on subjects related to their ...
Sofie Bergien, Clara M. Petersen, Marie Lynning, Maria Kristiansen, Lasse Skovgaard   +4 more
doaj   +1 more source

Cell-based therapeutic strategies for multiple sclerosis. [PDF]

, 2017
The availability of multiple disease-modifying medications with regulatory approval to treat multiple sclerosis illustrates the substantial progress made in therapy of the disease.
Cohen, Jeffrey A, International Conference on Cell-Based Therapies for Multiple Sclerosis, International Conference on Cell-Based Therapies for Multiple Sclerosis, International Conference on Cell-Based Therapies for Multiple Sclerosis, Pasquini, Marcelo, Reingold, Stephen C, Scolding, Neil J   +6 more
core   +1 more source

RAM-589.555 favors neuroprotective and anti-inflammatory profile of CNS-resident glial cells in acute relapse EAE affected mice

Journal of Neuroinflammation, 2020
Background Targeting RNA polymerase-1 (POL1) machinery is a new strategy for suppression of multiple sclerosis (MS) relapse activity. Oral administration of POL1 inhibitor RAM-589.555, which is characterized by high permeability and bioavailability in ...
Rina Zilkha-Falb, Tatyana Rachutin-Zalogin, Lakota Cleaver, Michael Gurevich, Anat Achiron   +4 more
doaj   +1 more source

A longitudinal study of abnormalities on MRI and disability from multiple sclerosis [PDF]

, 2002
Background: In patients with isolated syndromes that are clinically suggestive of multiple sclerosis, such as optic neuritis or brain-stem or spinal cord syndromes, the presence of lesions as determined by T2-weighted magnetic resonance imaging (MRI) of ...
Brex, P.A., Ciccarelli, O., Miller, D.H., O'Riordan, J.I., Sailer, M., Thompson, A.J.   +5 more
core   +1 more source